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Abstract
Background: Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from
acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone
marrow (BM) has not yet been performed. Profiles of arsenic speciation in plasma of BM were thus investigated
and compared with those of PB plasma from a relapsed APL patient. The total arsenic concentrations in high
molecular weight fraction (HMW-F) of BM and PB plasma were also determined.
Methods: Response assessment was evaluated by BM aspirate examination and fluorescence in situ hybridization
analysis. The analyses of total arsenic concentrations and speciation were preformed by inductively coupled plasma
mass spectrometry (ICP-MS), and high-performance liquid chromatography (HPLC)/ICP-MS, respectively.
Results: Response assessment showed that the patient achieved complete remission. The total arsenic
concentrations in BM plasma increased with time during the consecutive administration. The PB plasma
concentrations of methylated arsenic metabolites substantially increased after the start of administration, while
those of inorganic arsenic were still kept at a low level, followed by substantially increase from day-14 after
administration. The arsenic speciation profiles of PB plasma were very similar to those of BM plasma. Furthermore,
the total arsenic concentrations of HMW-F in BM plasma were much higher than those in PB plasma.
Conclusions: The behaviors of arsenic speciation suggested for the first time that arsenic speciation analysis of PB
plasma could be predicative for BM speciation, and showed relatively higher efficiency of drug metabolism in the
patient. These results may further provide not only significance of clinical application of ATO, but also a new
insight into host defense mechanisms in APL patients undergoing ATO treatment, since HMW proteins-bound
arsenic complex could be thought to protect BM from the attack of free arsenic species.
Keywords: Acute promyelocytic leukemia, Arsenic trioxide, Arsenic metabolite, Bone marrow, High-performance
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Introduction
Acute promyelocytic leukemia (APL) is a unique sub-
type of acute myeloid leukemia (AML) and accounts for
approximately 10-15% of all cases of AML in adults [1].
It is also characterized by a specific cytogenetic recipro-
cal chromosome translocations, t(15;17), generating
PML/RARa fusion gene, which is thought to play a cen-
tral role in the initiation of leukemogenesis [2-5]. An
introduction of all-trans retinoic acid (ATRA) since
1986 has dramatically improved the outcome of treat-
ment of this disease [3]. Nevertheless, an approximately
30% of the patients relapse and often become resistant
to the conventional treatment with ATRA alone, or in
combination with chemotherapy [5]. On the other hand,
investigators from China and the USA have demon-
strated that the treatment with arsenic trioxide (ATO,
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relapsed patients [1,6,7].
We have been investigating the effects of As(III) using
a unique in vitro system comprising primary cultured
chorion and amnion cells prepared from human fetal
membranes [8-10], and demonstrated that aquaporin 9
and multidrug resistance-associated protein 2 are func-
tionally involved in controlling arsenic accumulation in
these normal cells, which then contribute to differential
sensitivity to As(III) cytotoxicity between these cells
[11]. These findings may have broad important implica-
tions for revealing the mechanisms underlying the side
effects of ATO in patients. Furthermore, in order to
understand the mode of actions of ATO and provide an
effective treatment protocol for individual APL patients,
studies have been conducted on the pharmacokinetics of
ATO in APL patient using biological samples such as
urine, blood and cerebrospinal fluid [12-14]. In fact, we
recently demonstrated that various arsenic species
including inorganic arsenic and methylated arsenic
metabolites accumulated in red blood cells (RBCs) in an
APL patient [13]. We have also demonstrated for the
first time that these arsenic metabolites also existed in
cerebrospinal fluid [14], in which the total arsenic con-
centrations reached levels necessary for differentiation
induction [1,15]. These findings may provide a new
insight into clinical applications of ATO, and better
therapeutic protocols [16].
It has become clear that like hematopoietic stem cells,
leukemia stem cells (LSCs), which acquired limitless
self-renewal through oncogenic transformation, also
reside in bone marrow (BM) microenvironment, and
contribute to maintain the acute myeloid leukemia phe-
notype [17]. Recent studies have also demonstrated that
incomplete eradication of primary LSCs is closely linked
to chemotherapy resistance, and consequently contri-
bute to eventual disease relapse [17,18]. In this regard, it
is significant to note that targeting for the PML with
ATO could lead to loss of self-renewal capability of
LSCs in chronic myeloid leukemia (CML) based on the
studies on stem cells isolated from BM of human CML
patients and mouse bone marrow transplantation mod-
els [18]. These findings suggest that ATO would be a
promising candidate for a LSCs-targeted therapy and
raise a concern as to the detailed distribution profiles of
arsenic in BM. These ideas are based on previous find-
ings indicating that the total arsenic concentrations in
the plasma of BM from five relapsed APL patients were
close to levels for inducing differentiation, yet the analy-
sis was conducted for the BM sample collected at just
only one collection time point [19]. Furthermore, to the
best of our knowledge, no speciation analysis of arseni-
cals in BM from APL patients undergoing long-term
administration of ATO has been done before, despite
the fact that BM is a vital site for regulating the produc-
tion of blood cells.
It has been established that biomethylation is a major
metabolic pathway for inorganic arsenic in human
beings as well as many animal species, in which As(III)
is methylated to form trivalent and pentavalent products
such as methylarsonous acid (MA(III)), methylarsonic
acid (MA(V)), dimethylarsinous acid (DMA(III)),
dimethylarsinic acid (DMA(V)) [16]. Furthermore, it has
become clear that trivalent arsenicals can interact with
biological molecules of importance containing sulfhy-
dryls [20]. In fact, a study on complexes of trivalent
arsenicals with proteins has been conducted using organ
samples such as livers and kidneys in rats after an intra-
venous injection of arsenite [21]. However, no such stu-
dies have been conducted in biological samples from
APL patients undergoing ATO treatment. Furthermore,
the biological as well as clinical importance of proteins-
bound arsenic complex has been proposed [20,22], yet
the detailed studies have not been preformed.
In this study, we evaluated the clinical efficiency of
ATO in a relapsed APL patient undergoing long-term
administration of ATO by response assessment. In order
to obtain a general view regarding the pharmacokinetic
behaviors of ATO in APL patients, we also performed a
detailed systematic analysis of the accumulation of ATO
in RBCs as well as its metabolites in plasma of periph-
eral blood (PB). Most importantly, besides total arsenic
determination, we further investigated for the first time
the arsenic speciation in plasma of BM, and compared
the arsenic speciation profiles between PB and BM in
order to gain more detailed information on the distribu-
tion of arsenic. Furthermore, the total arsenic concen-
trations of high molecular weight fraction (HMW-F) in
BM and PB plasma were determined. Additionally, we
collected clinical samples just before (within 30 minutes)
the start of daily administration in order to get accurate
blood trough levels, since the levels are well known to
be closely related to clinical outcomes.
Patient and methods
Patient characterization
A 49-year-old Japanese woman was diagnosed with APL
in September 2003, and achieved first CR with ATRA.
C Rw a sk e p tu pt o1 5m o n t h sb yt h et r e a t m e n tw i t h
consolidation chemotherapy according to JALSG APL97
regimen [23]. However, she relapsed in April 2005.
After receiving reinduction therapy with ATRA, second
CR was obtained, followed by two 7-day course of con-
solidation chemotherapy comprising mitoxantrone 6
mg/m
2 intravenous (IV) bolus from day 5 to 7, etopo-
side 100 mg/m
2 IV administration for 1 h from day 1 to
day 5, and cytarabine (Ara-C) 150 mg/m
2 continuous IV
infusion for 24 h from day 1 to day 6 (MEC therapy).
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ber 2009.
Treatment protocol
The complete treatment protocol was approved by the
Internal Review Committee of Nihon University, and a
written informed consent was obtained from the study
patient before the treatment start. ATO monotherapy
was administered daily intravenously for 2 h at a dose of
0.15 mg/kg for 43 consecutive days. No critical compli-
cations such as disseminated intravascular coagulation
(DIC), organ failure, bleeding tendency, infectious dis-
ease, APL differentiation syndrome, or QT prolongation
on electrocardiogram were observed during the adminis-
tration period.
To evaluate the pharmacokinetics of arsenic species
precisely, we controlled the daily diet, in particular sea-
food, during the periods of remission induction therapy,
since arsenic compounds such as arsenobetaine (AB)
exist in seafood, and can make analysis complex during
remission induction and/or consolidation therapy [13].
Response assessment
Bone marrow aspirations for morphology and cytoge-
netics examination were performed by conventional
methods at Nihon University School of Medicine, Itaba-
shi Hospital, Tokyo, Japan. For morphologic response, a
clinical CR was defined as a bone marrow aspirate with
≤ 5% blast cells plus promyelocytes with no evidence of
leukemic cells [24,25]. Furthermore, flow cytometry ana-
lysis for cell surface markers of the blastoid fraction by
assessing the expression levels of CD11b and CD15
associated with myeloid maturation, and CD117 and
CD34 for primitive myeloid cells, were conducted at
SRL (Special Reference Laboratories, Tokyo, Japan).
Conventional cytogenetic test for t(15:17) was performed
by fluorescence in situ hybridization (FISH) analysis and
a negative FISH result was considered as a cytogenetic
complete remission.
Preparations of clinical samples
Blood and bone marrow samples were collected in an
EDTA-containing collection tube during the remission
induction therapy. Blood samples were collected before
treatment (day -1), and 3, 7, 10, 14, 17, 21, 28, 42, and
56 days after the start of administration. Bone marrow
aspirations were performed before treatment (day -1),
and 14, 28, 42, and 56 days after the start of administra-
tion. Both blood and bone marrow samples were col-
lected just before (within 30 minutes) the start of daily
administration, and the concentrations of arsenic at this
time-point were considered as its blood trough level
during the consecutive administration. Samples were
separated immediately into red blood cells and plasma
by centrifugation at 1,000 g for 10 min at 4°C. Subse-
quently, the RBCs and plasma were stored at -35°C until
analysis.
Sample preparations for arsenic analysis
Samples for total arsenic determination and arsenic spe-
ciation were prepared as described previously [13]. Since
it is difficult to measure volume of plasma and blood
cells correctly using a Pipetman due to a viscous nature
of samples, we measured weight of samples in each
experiment. Briefly, RBCs and plasma (0.2 g each) were
taken into a 15 mL polypropylene centrifuge tube. The
samples were mixed with HNO3 (0.5 mL) at room tem-
perature for 10 min, and incubated at 80-110°C on hot
plate after addition of 30% H2O2 (0.25 mL). They were
then diluted with Milli-Q water to 5 mL and filtrated
with 0.45 μm membrane filter (Millex-HA, MILLIPORE,
USA). Filtrates were subjected to total arsenic determi-
nation. On the other hand, in order to prepare samples
for arsenic speciation, the plasma (0.2 g) was ultrafil-
trated with a 10-kDa molecular mass cutoff (Micrcon
centrifugal filter devices 10,000 MWCO, Millipore,
USA). The filtrates were thus defined as low molecular
weight fraction (LMW-F) and subjected to arsenic spe-
ciation analysis. The remains trapped in filters were
defined as high molecular weight fraction (HMW-F) and
subjected to total arsenic determination.
Analysis of total arsenic concentrations and arsenic
speciation
The analysis of total arsenic concentrations and
arsenic speciation were performed by inductively
coupled plasma mass spectrometry (ICP-MS) (ELAN
DRC-e, PerkinElmer SCIEX, ON, Canada), and high-
performance liquid chromatography (HPLC) (LC
PU611 VS, GL Science, Tokyo, Japan)/ICP-MS,
respectively, as described previously [13]. CAPCELL
PAC C18 MG II (4.6 mm I.D. × 250 mm, Shiseido
Inc., Tokyo, Japan) was used as the separation column
on HPLC system, and MG II cartridge was attached as
a guard column to allow direct injection of biological
samples. The previously reported mobile phase condi-
tions for HPLC by our group [13] were used in the
current study. The retention times were determined
with TotalChrom Workstation version 6.2.0 (PerkinEl-
mer SCIEX, ON, Canada). The quantitation of arsenic
concentrations was performed by external calibration.
Concentrations of arsenic compounds were calculated
from a calibration curve of standard arsenic com-
pounds. The peak area was determined by Total-
Chrom Workstation version 6.2.0. As the standard
arsenic compounds, sodium arsenate (As(V)), sodium
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dimethylarsinic acid (DMA(V)) and arsenobetaine
(AB) were purchased from Tri Chemical Laboratories
Inc. (Yamanashi, Japan).
Results
Treatment efficacy
As shown in Table 1, the examination of bone marrow
aspirations showed that the percentage of blast cells plus
promyelocytes was 0.8% on day 28, and was kept less than
5% until day 56, although a transient increase was
observed on day 14, indicating that the clinical CR was
achieved on day 28. Furthermore, PML/RARa fusion gene
was not detected on day 56 by FISH testing, indicating
that the patient achieved cytogenetic CR after remission
induction therapy with ATO. Additionally, differentiation
induction of APL cells was confirmed by a substantial
increase in the expression levels of CD11b and CD15,
accompanying with a substantial decrease in the expres-
sion levels of CD117 and CD34 throughout the remission
induction therapy. Examination of bone marrow also
showed nuclear cell count of 4.0 to 12.0 × 10,000/μL con-
taining 21.6 to 51.2% of myeloid; 22.6 to 70.0% of ery-
throid; and 7.2 to 32.0% of others. Furthermore, peripheral
blood test results showed white blood cell count ranging
from 1.0 to 2.3 × 1,000/μL; neutrophil cell count ranging
from 0.15 to 1.1 × 1,000/μL; hemoglobin concentration
ranging from 10.9 to 13.6 g/dL; platelet count ranging
from 11.5 to 18.0 × 10,000/μL. During the remission
induction therapy, there was no requirement of any addi-
tional treatments for complications or blood transfusion.
Total arsenic concentrations in PB RBCs, PB plasma and
BM plasma
Profiles of total arsenic concentrations in the PB RBCs,
PB plasma and BM plasma are shown in Figure 1 and
summarized in Table 2. Total arsenic concentrations in
t h eP BR B C s ,a n dP Bp l a s m ar a n g e df r o m1 1 . 6n g A s / g
(day -1) to 184.8 ngAs/g (day 42), and from 5.55 ngAs/g
(day -1) to 55.5 ngAs/g (day 42), respectively, indicating
that total arsenic concentrations in RBCs and plasma of
PB increased with time during the consecutive adminis-
tration. Furthermore, total arsenic concentrations in the
PB RBCs were approximate 3 times higher than those in
PB plasma during the remission induction therapy. At
the same time period, total arsenic concentrations in the
BM plasma ranged from 7.59 ngAs/g (day -1) to 88.1
ngAs/g (day 42), indicating that arsenic accumulation
was observed in not only PB RBCs and PB plasma but
also BM plasma. Moreover, total arsenic concentrations
tended to be higher in the BM plasma than those in the
PB plasma. On the other hand, total arsenic concentra-
tions in these biological samples started decreasing
markedly from the last administration (day 42).
Arsenic speciation in PB plasma
A representative chromatogram of standard arsenic
compounds demonstrated the following elution order of
As(V), As(III), MA(V), DMA(V) and AB (Figure 2). A
representative merged chromatogram obtained from the
analyses of a plasma sample collected on day 14 and the
same plasma sample spiked with As(V), As(III), MA(V),
DMA(V), and AB is shown in Figure 3(A). Coelution of
the spiked arsenic standard with the suspected com-
pound in the plasma demonstrated their same chroma-
tographic behavior (Figure 3(A)). Furthermore, coelution
of the spiked arsenic standard with the suspected com-
pound in other plasma also demonstrated the same
chromatographic behavior (data not shown).
Profiles of As(V), As(III), MA(V), DMA(V) and AB are
s h o w ni nF i g u r e3 ( B )a n ds u m m a r i z e di nT a b l e3 .
Before the start of administration (day -1), no As(III)
and only a small amount of As(V), MA(V), and DMA
(V) were detected. However, after the start of adminis-
tration, the concentrations of MA(V) and DMA(V) sub-
stantially increased with time and almost reached a
plateau from day 21. Moreover, the concentrations of
DMA(V) tended to be higher than MA(V), especially in
the initial stage of administration (day 7-17), and even
after the last administration (from day 42). It should be
noted that As(III) concentrations substantially increased
from day 14 and the increase continued up to day 42,
although an apparent increase in the concentrations was
observed during the initial treatment period (from day 3
to day 10). Regarding As(V), the concentrations
increased slightly during the remission induction ther-
apy compared with those of other arsenic species.
Furthermore, the concentrations of DMA(V) and MA
(V) were still higher than those of other arsenic metabo-
lites on day 56, which is the day 13 after the last
Table 1 Response assessment during the remission
induction therapy
Days after the start of administration -1 14 28 42 56
Nuclear cell count (× 10
4/μL) 6.0 7.0 10.0 12.0 4.0
Blast+Promyelocyte (%) 5.8 17.8 0.8 1.2 0.6
Myeloid (%) 51.2 32.6 29.4 21.6 34.2
Erythroid (%) 22.6 28.8 55.0 70.0 33.2
Others (%) 20.4 20.8 14.8 7.2 32.0
PML-RARa FISH (%) 5.0 83.0 33.0 9.0 0.0
CD11b (%) 5.0 27.0 43.2 59.3 ND
CD15 (%) 8.6 23.2 38.5 47.2 ND
CD117 (%) 94.5 30.4 41.3 23.9 ND
CD34 (%) 38.0 14.4 26.2 15.8 ND
BM aspirations were collected before the treatment start (day -1), and 14, 28,
42, and 56 days after the start of administration. Response assessment was
evaluated by BM aspirate examination, FISH analysis and the expression levels
of cell surface markers. ND: no data.
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AB increased slightly and were maintained at almost the
same level except day 28 when compared with those of
the base line (day -1), which could be a result of seafood
intake at restaurant during the remission induction
therapy.
Arsenic speciation in BM plasma
Similar to arsenic speciation in PB plasma, identifica-
t i o no fa r s e n i cs p e c i e sb yas p i k et e s tw a sa l s oc o n -
ducted using a BM plasma sample collected on day 14.
Coelution of the spiked arsenic standard with the sus-
pected compound in the plasma demonstrated their
same chromatographic behavior (Figure 4(A)). Further-
more, coelution of the spiked arsenic standard with
the suspected compound in other plasma also demon-
strated the same chromatographic behavior (data not
shown).
Profiles of As(V), As(III), MA(V), DMA(V) and AB are
shown in Figure 4(B) and summarized in Table 4. Just
like in Figure 3(B) and Table 3, no As(III) and only a
small amount of As(V), MA(V), and DMA(V) were
detected on the day (day -1) before the start of adminis-
tration. However, the concentrations of MA(V) and
DMA(V) remarkably increased from day 14 and the
increase continued up to day 42, a profile of which is
similar to that observed in PB plasma. Moreover, the
concentrations of DMA(V) tended to be higher than
those of MA(V) in later stage of administration (from
day 28). Additionally, the concentrations of As(III) sub-
stantially increased from day 14 and reached its peak on
day 28, followed by declining over time. Similar to the
profiles of As(V) in PB plasma, its concentrations
increased slightly compared with those of other arsenic
species. Again, DMA(V) and MA(V) were still primary
metabolites in BM plasma as observed in PB plasma. As
expected, the alterations of AB concentrations caused by
patient’s seafood intake were also observed in BM
plasma.
Comparison of arsenic speciation profiles between PB
plasma and BM plasma
In order to clarify whether there is a similar arsenic spe-
ciation profiles in PB and BM plasma, we combined
arsenic speciation analysis data of PB and BM plasma
obtained at the same time point and summarized in Fig-
ure 5 and Table 5. Although a slight difference in the
concentrations of respective arsenic metabolites was
observed at each time point, the arsenic speciation pat-
tern between PB and BM plasma showed a close simi-
larity throughout the remission induction therapy.
Total arsenic concentrations in high molecular weight
fraction (HMW-F) of PB and BM plasma
We also determined total arsenic concentrations of
HMW-F in PB and BM plasma to obtain more detailed
profiles of arsenic distribution. The total arsenic concen-
trations of HMW-F were much higher in BM plasma
than those in PB plasma (Figure 6 and Table 6), indicat-
ing that the underlying reason for a higher total arsenic
c o n c e n t r a t i o ni nB Mp l a s m at h a ni nP Bp l a s m aa s
shown in Figure 1 is attributed to the difference in the
amount of arsenic contained in HMW-F, since the
amount of arsenic in LMW-F was almost the same.
Discussion
Administration of ATO has demonstrated a remarkable
efficacy in the treatment of relapsed and refractory APL
patients, who are generally resistant to the combinatory
conventional treatment protocol consisting of ATRA
Figure 1 Profiles of total arsenic concentrations in PB RBCs, PB
plasma and BM plasma collected during the remission
induction therapy. Symbols (●), (■) and (▲) show the total arsenic
concentrations in PB RBCs, PB plasma and BM plasma, respectively.
PB, peripheral blood; RBCs, red blood cells; BM, bone marrow.
Table 2 Total arsenic concentrations in PB RBCs, PB plasma and BM plasma collected during the remission induction
therapy
Days after the start of administration -1 3 7 10 14 17 21 28 42 56
Arsenic concentrations (ngAs/g) PB RBCs 11.6 106.2 141.4 149.7 149.4 128.2 142.7 163.6 184.8 53.7
PB Plasma 5.55 36.6 41.1 42.2 47.6 49.7 53.0 56.6 55.5 18.5
BM Plasma 7.59 ND ND ND 53.5 ND ND 72.1 88.1 20.4
Blood samples were collected before the treatment start (day -1), and 3, 7, 10, 14, 17, 21, 28, 42, 56 days after the start of administration. The total arsenic
concentrations in each clinical sample were determined by ICP-MS as described in “Patient and Methods”. ND: no data.
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these previous reports, the present study reconfirmed
the clinical efficacy of ATO in a relapsed APL patient
who achieved CR with ATRA once. Similar to a pre-
vious review report in which the median time to
achieve CR in patients treated with ATO alone ranged
from 28 to 38 days [27], the patient in the present
study also achieved CR on day 28 (Table 1). We also
demonstrated a substantial induction of APL cells dif-
ferentiation in the patient after the treatment with
ATO as evidenced by the alterations of the expression
levels of cell surface antigens associated with myeloid
maturation (Table 1). Results of the differentiation
induction are in good agreement with other experi-
mental results showing that a relatively lower dose of
ATO induces differentiation of freshly isolated APL
cells from patients as well as NB4 cells [1,2,15,16]. Of
note, there was no requirement of any additional treat-
ment for complications or blood transfusion and no
drug discontinuation throughout the remission induc-
tion therapy, although some clinical data failed to
return to a normal clinical reference range probably
due to immediate determination after treatment with
ATO. These results suggested that the patient would
be a good model for studying the pharmacokinetics as
well as the pharmacodynamics of ATO.
In agreement with our previous report [13], our pre-
sent results clearly demonstrated that the total arsenic
concentrations in either PB RBCs or PB plasma
increased with time during the consecutive administra-
tion, and that the majority of arsenic was present in the
RBCs (Figure 1 and Table 2). Therefore, careful atten-
tion should be paid to profiles of arsenic species in
RBCs. We also demonstrated for the first time a time-
dependent increase of the total arsenic concentrations in
BM plasma, which was similar to that in PB plasma
(Figure 1 and Table 2). Furthermore, the total arsenic
concentration levels tended to be higher in the BM
plasma than those in the PB plasma, raising clinical con-
cerns and inspiring us to unravel the detailed informa-
tion on the distribution of arsenic as well as its
speciation in these biological samples.
We have previously demonstrated that the PB plasma
concentrations of both methylated arsenic metabolites
(MA(V) and DMA(V)), and inorganic arsenic (As(V)
and As(III)) remarkably increased after the start of
administration in a Japanese APL patient undergoing
consolidation therapy [13]. Intriguingly, in the current
study, the concentrations of MA(V) and DMA(V)
increased substantially after the start of administration,
while those of As(III) were still kept at a low level until
day 10, followed by substantial increase from day 14
(Figure 3(B) and Table 3). It has been reported that in
many animal species including human beings, biomethy-
lation is a major metabolic pathway for inorganic
arsenic, through which arsenic undergoes metabolic
conversion by the reduction of As(V) to As(III) with
subsequent methylation, yielding MA(V) then to DMA
(V) [16,28,29]. Compared to the APL patient in our pre-
vious study [13], the patient enrolled in the current
study appeared to have relatively higher metabolic effi-
ciency probably due to her relatively young age or with-
out clinical complications. Results from previous studies
and our present study suggest that the efficiency of drug
metabolism is obviously different in individual patients
with different backgrounds, such as age range, with or
without organ failure or DIC, which in turn affect clini-
cal outcomes and appearance of side effects.
Figure 2 Chromatogram of standard arsenic species. The separation was performed on CAPCELL PAC C18 MG II with 10 mM butane sulfonic
sodium, 4 mM malonic acid, 4 mM tetramethylammonium hydroxide, and 0.5% methanol (pH 2.0). The signal peaks are as follows: As(V) (1), As
(III) (2), MA(V) (3), DMA(V) (4), and AB (5).
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ATO in Japanese patients with relapsed or refractory
APL [30] demonstrated that the PB plasma concentra-
tions of inorganic arsenic reached the steady state dur-
ing the consecutive administration, while the methylated
arsenic metabolites increased in relation to administra-
tion frequency. On the other hand, our recent study
involving an APL patient with first relapse demonstrated
that the PB plasma concentrations of both inorganic
arsenic and methylated arsenic metabolites increased
Figure 3 Profiles of concentrations of arsenic species in PB plasma collected during the remission induction therapy. Blood samples
were collected before the treatment start (day -1), and 3, 7, 10, 14, 17, 21, 28, 42, 56 days after the start of administration. The concentrations of
arsenic species in plasma were determined with HPLC/ICP-MS as described in “Patient and Methods.” A merged representative chromatogram
obtained from the analyses of a plasma sample collected on day 14 and the same plasma sample spiked with As(V), As(III), MA(V), DMA(V), and
AB is shown in Figure 3(A). The signal peaks are as follows: As(V) (1), As(III) (2), MA(V) (3), DMA(V) (4), and AB (5). The concentrations of arsenic
species calculated from these chromatograms are shown in Figure 3(B). (●): As(V); (■): As(III); (▲): MA(V); (♦): DMA(V); (O): AB.
Table 3 Arsenic concentrations in PB plasma collected during the remission induction therapy
Days after the start of administration -1 3 7 10 14 17 21 28 42 56
Arsenic concentrations (ngAs/g) As(V) 0.36 0.96 0.69 0.99 1.26 1.03 1.34 1.50 0.99 0.24
As(III) 0 1.50 1.86 2.02 6.31 5.89 5.74 7.89 5.83 0.09
MA(V) 0.55 6.91 8.30 10.46 10.59 10.24 13.99 13.50 14.05 1.87
DMA(V) 0.11 6.14 10.3 12.2 13.2 14.0 14.0 13.3 15.3 3.96
AB 0.60 1.94 1.06 1.39 0.43 1.04 0.88 3.80 0.99 1.22
Blood samples were collected before the treatment start (day -1), and 3, 7, 10, 14, 17, 21, 28, 42, 56 days after the start of administration. The concentrations of
arsenic species in PB plasma were determined by HPLC/ICP-MS as described in “Patient and Methods”.
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toward reaching a plateau in these arsenic species was
observed in PB plasma in the current study (Figure 3(B)
and Table 3). These results clearly suggest that arsenic
metabolism among individual patients were different. A
similar observation was reported by Wang et al. [12], in
which there are interindividual differences in excretion
profiles and the relative concentrations of major arsenic
species in urine among four Chinese APL patients
undergoing ATO treatment. It is significant to note that
genetic polymorphisms in arsenic metabolism genes,
such as human arsenic methyltransferase (AS3MT) gene
and glutathione S-transferase gene, are considered to be
related to interindividual variation in the arsenic meta-
bolism [31-33]. Collectively, continuous efforts to under-
stand the differences in arsenic metabolism and the
relationship between these genetic polymorphisms and
arsenic metabolism among patients are definitely useful
for providing an effective treatment protocol of ATO
for individual APL patients, ultimately contribute to
reduction of its side effects. Moreover, it should be
Figure 4 Profiles of concentrations of arsenic species in BM plasma collected during the remission induction therapy.B Ma s p i r a t e s
were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The concentrations of arsenic
species in plasma were determined with HPLC/ICP-MS as described in “Patient and Methods.” Similar to Figure 3 (A), identification of arsenic
species by a spike test was conducted using a plasma sample collected on day 14 and was shown in Figure 4 (A). The concentrations of arsenic
species calculated from these chromatograms are shown in Figure 4 (B). (●): As(V); (■): As(III); (▲): MA(V); (♦): DMA(V); (O): AB.
Table 4 Arsenic concentrations in BM plasma collected
during the remission induction therapy
Days after the start of administration -1 14 28 42 56
Arsenic concentrations (ngAs/g) As(V) 0.35 0.54 1.91 2.34 0.17
As(III) 0 3.43 7.47 4.00 0.10
MA(V) 0.80 12.4 12.4 13.0 1.63
DMA(V) 0.63 11.5 12.1 15.1 3.21
AB 0.51 3.49 0.50 0.99 1.00
BM aspirates were collected before the treatment start (day -1), and 14, 28,
42, and 56 days after the start of administration. The concentrations of arsenic
species in BM plasma were determined by HPLC/ICP-MS as described in
“Patient and Methods”.
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profiles between PB and BM plasma was observed
throughout the remission induction therapy (Figure 5
and Table 5). These results thus suggested for the first
time that arsenic speciation analysis of PB plasma could
be predicative for BM speciation without applying BM
aspiration.
We then focused on the total amount of arsenic in
HMW-F trapped in a 10-kDa molecular mass cutoff fil-
ters and demonstrated that its concentrations were
much higher in BM plasma than those in PB plasma
(Figure 6 and Table 6). One important biological effects
of arsenic has been suggested to be mediated by reac-
tion with closely spaced cysteine residues on critical cell
protein [34]. Several proteins such as tubulin, thiore-
doxin reductase, AS3MT with a high cysteine content
and accessible thiol group are candidates for interactions
with arsenic [16,20]. In fact, arsenic bound to high
molecular weight proteins (MW > 10-kDa) has been
detected in livers and kidneys in rats after an
Figure 5 Comparison of arsenic speciation profiles between PB plasma and BM plasma. The columns of Before start, Day-14, Day-28, Day-
42 and Day-56 represent the speciation profiles of PB and BM plasma collected before the treatment start (day -1), and 14, 28, 42, and 56 days
after the start of administration, respectively. The open column, gray column, black column, hatched column and vertical striped column show
As(V), As(III), MA(V), DMA(V) and AB, respectively.
Table 5 Arsenic concentrations in PB and BM plasma collected during the remission induction therapy
Days after the start of administration -1 14 28 42 56
Clinical samples PB BM PB BM PB BM PB BM PB BM
Arseni concentrations (ngAs/g) As(V) 0.36 0.35 1.26 0.54 1.50 1.91 0.99 2.34 0.24 0.17
As(III) 0 0 6.31 3.43 7.89 7.47 5.83 4.00 0.09 0.10
MA(V) 0.55 0.80 10.6 12.4 13.5 12.4 14.0 13.0 1.87 1.63
DMA(V) 0.11 0.63 13.2 11.5 13.3 12.1 15.3 15.1 3.96 3.21
AB 0.60 0.51 0.43 3.49 3.80 0.50 0.99 0.99 1.22 1.00
Blood samples and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The
concentrations of arsenic species in PB and BM plasma were determined by HPLC/ICP-MS as described in “Patient and Methods”.
Figure 6 Total arsenic concentrations in HMW-F and LMW-F of
PB and BM plasma. Blood samples and BM aspirations were
collected before the treatment start (day -1), and 14, 28, 42, and 56
days after the start of administration. HMW-F of PB and BM plasma
were prepared and subjected to total arsenic determination as
described in “Patient and Methods”. The total arsenic concentrations in
LMW-F of PB and BM plasma were obtained by subtraction of that in
HMW-F from the total arsenic concentrations in PB and BM plasma.
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role of BM microenvironment in maintaining the home-
ostasis of hematopoietic system, we assumed that a
higher amount of proteins (MW > 10-kDa)-bound
arsenic complex contribute to protection effect from the
attack of free arsenic species. Likewise, the patients with
low-proteinemia besides liver and/or renal dysfunctions
might frequently develop arsenic-mediated side effects.
Understandably, further investigation of the detailed
information about these proteins is needed.
In conclusion, we clarified the arsenic speciation for
the first time in BM plasma, and found that speciation
profiles of BM plasma were very similar to those of PB
plasma. We also demonstrated that the total arsenic
concentrations of HMW-F were much higher in BM
plasma than those in PB plasma. These results may
further provide not only significance of clinical applica-
tion of ATO, but also a new insight into host defense
mechanisms in APL patients undergoing ATO treat-
ment. Of note, it has been demonstrated that targeting
for the PML with ATO could lead to loss of self-renewal
capability of LSCs, which is closely linked to chemother-
apy resistance and disease relapse, in CML [18], suggest-
i n gt h a tA T Ow o u l db eap r o m i s i n gc a n d i d a t ef o ra
LSCs-targeted therapy [17]. Our results thus may pro-
vide new evidence for LSCs-targeted therapy in APL
patients based on the following facts: 1) PML-RARa can
be detected in more than 95% of APL patients [2], 2)
long-term follow-up of newly diagnosed patients with
APL treated with single ATO therapy shows a high 5-
year disease-free survival (DFS) rate and overall survival
(OS) rate [35-37]. It is well known that the blood trough
levels correlated with clinical benefit better than either
maximum levels or area under the curve (AUC). Similar
to our and other group’s previous reports [13,38], the
plasma trough levels of As(III) were much lower com-
pared to a previous report [6]. These results thus leave
open a possibility that much lower concentrations of As
(III) possess biological effects such as differentiation-
inducing activity, although we could not exclude
whether other arsenicals, such as As(V) and methylated
arsenic metabolites, alone or their combination contri-
bute to the effects based on a previous report showing
that methylated arsenic metabolites also possess cytoci-
dal activity against leukemia and lymphoma cells, conse-
quently may contribute to the therapeutic effect of ATO
in APL patients [39]. Details of the study are currently
underway.
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